#China #Shanghai #Healthcare Innovation #Biotech Startups #Med-Fine Capital

Med-Fine Capital Closes New USD Fund, Advancing China Biotech's Global Innovation and Expansion

Shanghai, June 16, 2025 /PRNewswire/ – Med-Fine Capital, a venture capital firm that specializes in early-stage healthcare innovation in China, has announced the successful closing of its second USD fund. This new fund represents a significant step forward as it will continue to channel investments into cutting-edge biotech startups, propelling the next generation of healthcare technologies across the globe.

Resilient Investor Confidence Amidst Market Adjustments

The closure of this fundraising round comes at a crucial point as the biotech investment landscape in China is currently experiencing adjustments. Jack Zhou, the Managing Partner at Med-Fine Capital, remarked on the importance of the trust that investors continue to place in the firm: "In today's environment, the ongoing confidence and backing from our investors is invaluable. It is not just a testament to our past accomplishments and professional expertise but also serves as a robust vote of confidence in Med-Fine's strategy for global expansion."

Positive Outlook for Biotech Innovation in China

1. Rising Innovation Strength: Between 2015 and 2024, innovative drugs from China that received global first-time approvals surged from 3 to an impressive 39 — a twelvefold increase that enhanced China's ranking from third to second worldwide for drug innovations. Concurrently, Chinese biotech firms have accelerated their global outreach through cross-border business transactions, culminating in a remarkable transaction value of USD 63.5 billion in 2024, marking a 22.59% year-on-year growth. The standout feature of the year was the 24 mega-deals, each exceeding USD 1 billion, amounting to a collective USD 43 billion — nearly 20% of the global market for such transactions.

2. Hong Kong Capital Market Rebound: In May 2025, the Hong Kong stock market recorded an initial public offering (IPO) total of HKD 55.8 billion, the highest rate since March 2021. By the end of the year, the fundraising amount had reached HKD 77.4 billion, nearly 90% of the total raised in 2024. The performance of the Hang Seng Tech Index also stood out, experiencing a significant rise of 14.9%, markedly outperforming other major global markets.

3. Exceptional Investment Capabilities: The investment team at Med-Fine Capital is distinguished by its in-depth industry knowledge, expansive global networks, and proven investment acumen, which offer a solid foundation for identifying lucrative opportunities in the biotech sector.

A Decade-Long Commitment to Early-Stage Innovation

Over the past ten years, Med-Fine Capital has consistently honed in on the Chinese biotech innovation ecosystem. Guided by their investment philosophy aimed at discovering and nurturing early-stage opportunities, the firm has successfully invested in over 60 innovative startups to date. The recent fund marks the firm’s second USD offering, signaling Med-Fine's robust entry and steady growth in the USD investment market, backed by reputable limited partners that include global funds of funds, Hong Kong financial institutions, Singaporean family offices, and corporations associated with the healthcare sector.

Backing Startups with a Global Perspective

"The investment team at Med-Fine Capital brings together strong industry expertise complemented by extensive global experience, allowing us to focus on oncology, autoimmune conditions, metabolic diseases, and CNS disorders — investing in innovative solutions that stand out on a global stage," remarked Dr. Vince Deng, Partner and Head of Biotech Investment at Med-Fine Capital. The firm actively aids promising Chinese biotech firms in navigating the complexities of global markets, supporting critical areas such as research and development, clinical advancement, and regulatory compliance during their international expansion.

Med-Fine's strategic approach goes beyond making quick investments; it encompasses comprehensive support to entrepreneurs aimed at achieving outstanding returns. By adopting a philosophy that focuses on the 'end in mind,' the firm seeks to shape the development of companies by critically evaluating market needs and exit strategies. "We place great importance on co-founding new ventures with experienced entrepreneurs while pinpointing the most viable directions and assets at the right time to mitigate investment risks and maximize returns. This mindset has led us to co-found and invest in several promising biotech firms through this new fund, such as Allink Biotherapeutics and VelaVigo, many of which have secured subsequent funding rounds led by top-tier investors. These achievements bolster our confidence and inspire us to continue executing our tried-and-true investment strategies," added Dr. Deng.

Long-Term Partnerships with a Global Vision

Jack Zhou emphasized the importance of Med-Fine Capital's philosophy, stating: "We are committed to investing in globally competitive asset pipelines. Our role extends beyond that of a mere capital provider; we strive to be long-term strategic partners with our portfolio companies. We aim to establish a research-driven investment framework that prioritizes clinical value and technological innovation while keeping global market demands and unmet medical needs in our sights. We continuously enhance our strengths in cross-border resource integration and value investment across varying market cycles to better the lives of patients worldwide."

About Med-Fine Capital

Med-Fine Capital is a venture capital firm dedicated to healthcare and life sciences investments. Backed by a management team with extensive global insights, deep industry knowledge, valuable resources, and professional investment experience, Med-Fine manages multiple RMB and USD funds. The firm is primarily focused on uncovering early-stage value in biotech, medical devices, diagnostics, digital health, and healthcare services. To date, it has successfully invested in over 60 companies, including notable names such as Mabworks, Eccogene, Zion, LYNK, and others.